Summary
In order to evaluate a twice daily dosage regimen of bacampicillin a multicenter clinical trial was performed in patients suffering from pelvic inflammatory disease (PID). A total of 75 patients were allocated at random to treatment with 800 mg bacampicillin twice daily or 400 mg three times daily for fourteen days (PID). The study was performed double-blind. The therapeutic effect was assessed in 70 patients. The therapeutic response was judged on the basis of clinical symptoms and bacteriology. There was no significant difference in the overall efficacy of the two dosages in the patient groups studied. Good response was obtained in 93% of the patients, and 7% were improved. Gastrointestinal side-effects were infrequent (three cases out of 75). Exanthema occurred in six patients.
Zusammenfassung
Zur Beurteilung einer zweimal täglichen Dosierung von Bacampicillin wurde bei Patienten mit entzündlichen Erkrankungen der Organe des kleinen Beckens eine klinische multizentrische Studie durchgeführt. Insgesamt 75 Patienten wurden zufallsgemäß mit entweder 800 mg Bacampicillin zweimal täglich oder 400 mg dreimal täglich über vierzehn Tage behandelt. Die Studie wurde nach klinischen Symptomen und bakteriologischen Befunden bei insgesamt 70 Patienten beurteilt. Es konnte kein signifikanter Unterschied zwischen den beiden Dosierungen festgestellt werden. Gute Resultate wurden bei 93% der Patienten erreicht, 7% wurden gebessert. Zu gastrointestinalen Beschwerden kam es selten (bei drei von 75 Patienten). In sechs Fällen trat ein Exanthem auf.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Literature
Bodin, N.-O., Ekström, B., Forsgren, U., Jalar, L.-P., Magni, L., Ramsay, C.-H., Sjöberg, B. Bacampicillin, a new orally well absorbed derivative of ampicillin. Antimicrob. Agents Chemother. 8 (1975) 518–525.
Maesen, F. P. V., Beeuwkes, H., Davies, B. I., Buytendijk, H. J., Brombacher, P. J., Wessman, J. Bacampicillin in acute exacerbations of chronic bronchitis — a dose/range study. J. Antimicrob. Chemother. 2 (1976) 279–285.
Magni, L., Sjövall, J., Syvälahti, E. Comparative clinical pharmacology of bacampicillin and high oral doses of ampicillin. Infection 6 (1978) 283–289.
Sjövall, J., Magni, L., Bergan, T. Pharmacokinetics of bacampicillin compared with those of ampicillin, pivampicillin, and amoxycillin. Antimicrob. Agents Chemother. 13 (1978) 90–96.
Davies, B. I., Maesen, F. P. V., Brombacher, P. J., Sjövall, J. Twice daily dosage of bacampicillin in chronic bronchitis. A double-blind study. Scand. J. Resp. Dis. 59 (1978) 249–256.
Tuomaala, R. Bacampicillin and ampicillin in general practice: double-blind comparison in urinary tract infections. In:Siegenthaler, E., Lüthy, R. (eds.): Current Chemotherapy I. American Society of Microbiology, Washington D. C. 1978, pp. 207–208.
Weström, L., Mårdh, P.-A. Acute salpingitis. Aspects on aetiology, diagnosis, and prognosis. In:Danielsson, D., Juhlin, L., Mårdh, P.-A. (eds.): Genital infections and their complications. A Wellcome Foundation Symposium. Almqvist & Wiksell International, Stockholm 1975, pp. 157–167.
Paavonen, J., Saikku, P., Vesterinen, E., Aho, K. Chlamydia trachomatis in acute salpingitis. Br. J. Vener. Dis. 55 (1979) 203–206.
Chow, A. W., Patten, V., Marshall, J. R. Bacteriology of acute pelvic inflammatory disease. Suboptimal survival ofNeisseria gonorrhoeae in a nonbuffered transport system. Am. J. Obstet. Gynecol. 133 (1979) 362–365.
Monif, G. R. G., Welkos, S. L., Baer, H., Thompson, R. J. Culde-sac isolates from patients with endometritis-salpingitis-peritonitis and gonococcal endocervicitis. Am. J. Obstet. Gynecol. 126 (1976) 158–161.
Eschenbach, D. A., Buchanan, T. M., Pollock, H. M., Forsyth, P. S., Alexander, E. R., Lin, J.-S., Wang, S.-P., Wentworth, B. B., McCormack, W. M., Holmes, K. K. Polymicrobial etiology of acute pelvic inflammatory disease. N. Engl. J. Med. 293 (1975) 166–171.
Bengtsson, S., Erikson, G., Kallings, L.-O., Moberg, I., Sandström, E., Wallin, J., Wallmark, G. A clinical dose-response study of bacampicillin in uncomplicated gonorrhoea. J. Antimicrob. Chemother. 5 (1979) 211–218.
Hedberg, E., Jonassen, F. Ampicillin vid behandling av gonorroisk salpingit. Läkartidn. 68 (1971) 335–340.
Lindhe, B. Å. Comparative study of methods of treating acute salpingitis. Läkartidn. 72 (1975) 837–838.
Grech, E. S., Mutale, E. M., Bathirunatham, N. Treatment of acute pelvic infections with alphacillin (pivampicillin HCl). Med. J. Zambia 11 (1977) 99–103.
Lind, I. Identification ofNeisseria gonorrhoeae by means of fluorescent antibody technique. Acta Pathol. Microbiol. Scand. 70 (1967) 613–629.
Reyn, A. Bacteriological examination for gonorrhoea. Ugeskr. Laeger 135/20 (1973) 909–913.
Nordbring, F. Review of side-effects of aminopenicillins. Infection 7 Suppl. 5 (1979) 503–506.
Croydon, E. A. P., Wheeler, A. W., Grimshaw, J. J., Atkins, W., Cowan, M. A., Geddes, A. M., Jain, S., Yassa, J. G., Beveridge, G. W., Gray, J. A., Mordoc, J. McC., Pullen, H., Rowell, N. R., Stevenson, J. Prospective study of ampicillin rash. Report of a collaborative study group. Br. Med. J. 1 (1973) 7–9.
Pauwels, R., Detiége, J. J. Deux prises quotidiennes de bacampicilline dans le traitement des infections des voies respiratories en pratique de médecine générale. Ars Medici 35 (1980) 529–543.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grafford, K., Guttorm, E., Kristensen, G.B. et al. Bacampicillin in the treatment of pelvic inflammatory disease: A study of two dosage regimens. Infection 8, 290–292 (1980). https://doi.org/10.1007/BF01640921
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01640921